Cyanobacterial extract with serotonin receptor subtype 7 (5-HT 7 R) affinity modulates depression and anxiety-like behavior in mice

Neil C. Lax, Stacy Ann J. Parker, Edward J. Hilton, Youstina Seliman, Kevin J. Tidgewell, Benedict J. Kolber

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Marine cyanobacteria represent a unique source in the field of drug discovery due to the secondary metabolites they produce and the structural similarity these compounds have to endogenous mammalian receptor ligands. A series of cyanobacteria were subjected to extraction, fractionation by column chromatography and screened for affinity against CNS targets with a focus on serotonin receptors (5-HTRs). Out of 276 fractions screened, 21% had activity at 5-HTRs and/or the 5-HT transporter (SERT). One sample, a cyanobacterium identified by 16S rRNA sequencing as Leptolyngbya from Las Perlas archipelago in Panama, contained a fraction with noted affinity for the 5-HT 7 receptor (5-HT 7 R). This fraction (DUQ0002I) was screened via intracerebroventricular (ICV) injections in mice using depression and anxiety assays including the forced swim, tail suspension, elevated zero maze, and light-dark preference tests. DUQ0002I decreased depression and anxiety-like behaviors in males and did not have effects in 5-HT 7 R knockout or female mice. Administration of DUQ0002I to the CA1 of the hippocampus induced antidepression-like, but not anxiolytic-like behaviors. Testing of further purified materials showed no behavioral effects, leading us to hypothesize that the behavioral effects are likely caused by a synergistic effect between multiple compounds in the fraction. Finally, DUQ0002I was used in a model of neuropathic pain with comorbid depression (spared nerve injury—SNI). DUQ0002I had a similar antidepressant effect in animals with SNI, suggesting a role for the 5-HT 7 R in the development of comorbid pain and depression. These results demonstrate the potential that cyanobacterial metabolites have in the field of neuropharmacognosy.

Original languageEnglish
Article numbere22059
JournalSynapse
Volume72
Issue number11
DOIs
StatePublished - Nov 2018

Bibliographical note

Publisher Copyright:
© 2018 Wiley Periodicals, Inc

Funding

We thank the Autoridad Nacional del Ambiente (ANAM), Panama for permission to make and export collections of marine cyanobacteria and the Smithsonian Tropical Research Institute (STRI) for use of boat and facilities in Panama. We would also like to thank Kh Tanvir Ahmed for sample preparations used in behavioral testing, Analise Zapadka for her work with 16S rRNA sequencing, and Anna Polaski and Heather Allen for their manuscript editing. Project was funded through (1) a grant provided by the American Pain Society and the Sharon S. Keller Fund for Chronic Pain Research (BJK and KJT), (2) a grant from the NIH (NCCIH R15AT008060; BJK and KJT), (3) a Fogarty International Center (FIC) International Cooperative Biodiversity Group (ICBG) grant based in Panama (2U01TW006634-06; KJT), and (4) a grant from the Duquesne University Faculty Development Fund (KJT and BJK). Ki determinations and receptor binding profiles were generously provided by the National Institute of Mental Health’s Psychoactive Drug Screening Program, Contract # HHSN-271-2008-025C (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda MD, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the Autoridad Nacional del Ambiente (ANAM), Panama for permission to make and export collections of marine cyanobacteria and the Smithsonian Tropical Research Institute (STRI) for use of boat and facilities in Panama. We would also like to thank Kh Tanvir Ahmed for sample preparations used in behavioral testing, Analise Zapadka for her work with 16S rRNA sequencing, and Anna Polaski and Heather Allen for their manuscript editing. Project was funded through (1) a grant provided by the American Pain Society and the Sharon S. Keller Fund for Chronic Pain Research (BJK and KJT), (2) a grant from the NIH (NCCIH R15AT008060; BJK and KJT), (3) a Fogarty International Center (FIC) International Cooperative Biodiversity Group (ICBG) grant based in Panama (2U01TW006634-06; KJT), and (4) a grant from the Duquesne University Faculty Development Fund (KJT and BJK). Ki determinations and receptor binding profiles were generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract # HHSN-271-2008-025C (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda MD, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

FundersFunder number
Autoridad Nacional del Ambiente
National Institutes of Health (NIH)
National Institute of Mental HealthHHSN-271-2008-025C
Fogarty International Center2U01TW006634-06
National Center for Complementary and Integrative HealthR15AT008060
Smithsonian Tropical Research Institute
American Society for Pain Management Nursing
Duquesne University

    Keywords

    • animal models
    • anxiety
    • behavior
    • cyanobacteria
    • depression
    • drug discovery
    • serotonin receptor 7

    ASJC Scopus subject areas

    • Cellular and Molecular Neuroscience

    Fingerprint

    Dive into the research topics of 'Cyanobacterial extract with serotonin receptor subtype 7 (5-HT 7 R) affinity modulates depression and anxiety-like behavior in mice'. Together they form a unique fingerprint.

    Cite this